Provided by Tiger Fintech (Singapore) Pte. Ltd.

Compass Therapeutics, Inc.

1.75
+0.05002.94%
Post-market: 1.760.0100+0.57%19:27 EDT
Volume:691.69K
Turnover:1.20M
Market Cap:241.99M
PE:-4.87
High:1.78
Open:1.69
Low:1.68
Close:1.70
Loading ...

Compass Therapeutics reports Q4 EPS (11c), consensus (9c)

TIPRANKS
·
27 Feb

Compass Therapeutics Inc.: 2024-End Cash & Marketable Securities Expected to Provide Cash Runway Into Q1 2027

THOMSON REUTERS
·
27 Feb

Compass Therapeutics Reports 2024 Financial Results and Provides Corporate Update

GlobeNewswire
·
27 Feb

Guggenheim Initiates Compass Therapeutics at Buy With $12 Price Target

MT Newswires Live
·
24 Feb

Compass Therapeutics Inc. : Guggenheim Initiates Coverage With Buy Rating; Price Target $12

THOMSON REUTERS
·
24 Feb

Compass Therapeutics initiated with a Buy at Guggenheim

TIPRANKS
·
24 Feb

Piper Sandler Initiates Compass Therapeutics at Overweight

MT Newswires Live
·
19 Feb

BUZZ-Piper Sandler initiates coverage on Compass Therapeutics with 'overweight' rating

Reuters
·
19 Feb

Compass Therapeutics Initiated at Overweight by Piper Sandler

Dow Jones
·
19 Feb

Buy Rating for Compass Therapeutics Driven by Promising Tovecimig Results and Strategic Pipeline

TIPRANKS
·
19 Feb

Compass Therapeutics Inc. : Piper Sandler Initiates Coverage With Overweight Rating; Target Price $12

THOMSON REUTERS
·
19 Feb

Optimistic Buy Rating for Compass Therapeutics Due to Promising CTX-009 Trial Results and Market Potential

TIPRANKS
·
11 Feb

Compass Therapeutics price target raised to $8 from $7 at Jefferies

TIPRANKS
·
11 Feb

Compass Therapeutics Inc. : Jefferies Raises Target Price to $8 From $7

THOMSON REUTERS
·
10 Feb

Dell Stock Set to Benefit From AI and Cloud Applications, Analyst Says. Plus, Twilio, Tradeweb, and More. -- Barrons.com

Dow Jones
·
11 Jan

Compass Therapeutics Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

Dow Jones
·
10 Jan

Compass Therapeutics: Strategic Advancements and Promising Pipeline Justify Buy Rating

TIPRANKS
·
09 Jan

Compass Therapeutics: Strong Growth Potential Bolstered by Upcoming Milestones and Strategic Focus

TIPRANKS
·
08 Jan

BRIEF-Compass Therapeutics Provides Corporate Update And Announces Advancement Of A New Drug Candidate

Reuters
·
08 Jan

Compass Therapeutics Inc.: Expect to Submit an Ind by End of 2025 for Ctx-10726

THOMSON REUTERS
·
08 Jan